SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Otros idiomas Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Acciones

600196

CNE000000X38

Precio de cierre Shanghai S.E. Otros sitios de cotización 00:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
23,19 ^CNY	+1,35 %		+3,02 %	-7,35 %

24/04	La unidad de Fosun Pharma obtiene la aprobación del regulador chino para el registro de comercialización de un medicamento contra la tuberculosis	MT
08/04	China acepta las solicitudes de nuevos medicamentos para el síndrome de sobrecarga de hierro de Fosun Pharma	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24/04
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18/04
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08/04
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	31/03
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26/03
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14/03
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	08/03
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	08/03
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	04/03
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	01/03
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	20/02
Yuyuan Tourist Mart CFO Steps Down	05/02
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	25/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Acciones

600196

CNE000000X38

Otros idiomas

Filtros